Creo
Medical Group plc
("Creo"
the "Company" or the "Group")
Posting of 2023 Annual Report and
Accounts
and
Notice of Annual General
Meeting
Creo Medical Group plc (AIM: CREO),
the medical device company focused on the emerging field of
surgical endoscopy, announces that the Annual Report and Accounts
for the year ended 31 December 2023 and the Notice of the Company's
Annual General Meeting ("AGM") have now been published on the
Company's website at https://www.creomedical.com/en/investors/reports-and-presentations,
with hard copies being posted to those shareholders who have not
elected to receive electronic communication from the
Company.
The AGM will be held on
Wednesday, 26 June 2024 at 10:00am at Creo House, Beaufort Park,
Beaufort Park Way, Chepstow NP16 5UH and will consider the
Resolutions set out in the Notice of AGM. The Company's CEO, Craig
Gulliford, will make a short presentation at the meeting. No
new material information will be included within the
presentation.
Shareholders are encouraged to vote
by proxy at the AGM, which can be done:
·
by completing, signing the Form of Proxy and
returning it to Equiniti; or
·
in the case of CREST members, by utilising the
CREST electronic proxy appointment service.
Proxy votes must be received no
later than 10:00am on 24 June 2024. Shareholders are recommended to
appoint the Chair of the meeting as their proxy rather than a named
person, as any such other person may not be permitted to attend the
AGM in the event of unforeseen circumstances (e.g.
illness).
Voting will be conducted on each
Resolution by way of a poll.
Enquiries:
|
Creo Medical
Group plc
|
www.creomedical.com
|
|
Richard Rees (CFO)
|
+44 (0)1291 606
005
|
|
|
|
|
Cavendish
Capital Markets Limited
|
+44 (0)20 7397
8900
|
|
Stephen Keys / Camilla Hume (NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan
Brown
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook
PR
|
Tel: +44
(0)20 7933 8780 or
creo@walbrookpr.com
|
|
Paul McManus / Sam Allen
Phillip Marriage
|
Mob: +44
(0)7980 541 893 / +44 (0)7502 558 258
+44
(0)7867 984 082
|
About Creo
Medical
Creo Medical is a medical device company
focused on the development and commercialisation of minimally
invasive electrosurgical devices, bringing advanced energy to
endoscopy.
The Company's vision is to improve patient
outcomes through the development and commercialisation of a suite
of electrosurgical medical devices, each enabled by CROMA, powered
by Kamaptive. The Group has developed the CROMA powered by
Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less-invasive and more
cost-efficient option for procedures.
For more information, please refer to the
website www.creomedical.com
